All In Biotech

Drug Trial Radar · NCT06722664

Efficacy and Safety of OsrhCT and Dimethicone Emulsion Before Upper Endoscopy on Visualization of the Gastric Mucosa.

A Phase 2 , Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Using Premedication With OsrhCT and Dimethicone Emulsion During Upper Gastrointestinal Endoscopy Examination.

Last checked: Nov 19, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 336 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

336

Planned (sponsor's estimate)

Start

Dec 19, 2024

Primary completion

May 15, 2025

Study completion May 15, 2025

Sponsor

Lead sponsor
Healthgen Biotechnology Corp.Industry
Sponsor type
Industry
Collaborators
Beijing Friendship Hospital
First posted
Dec 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study was designed to evaluate efficacy of OsrhCT and Dimethicone emulsion before upper endoscopy on visibility of gastric mucosa. A total of 336 subjects (both male and female) are expected to be enrolled in this trial.

Conditions

  • Gastric Mucosal Lesion

Interventions

  • Recombinant Human Chymotrypsin(OsrhCT) 4000UDrug

    Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 4,000U/vial, freeze-dried powder

  • Placebo for Recombinant Human Chymotrypsin(OsrhCT)Drug

    Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 0 U/vial, freeze-dried powder

  • Dimethicone emulsion 4mlDrug

    Dimethicone emulsion,produced by Sichuan Jian Neng Pharmaceutical Co., Ltd, 6ml/bottle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total visibility score (TVS) evaluated by blinded endoscopistsTime frame: Through study completion, an average of 3 months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Friendship Hospital

    Beijing, Beijing Municipality, China

  • Chinese PLA Central Theatre General Hospital

    Wuhan, Hubei, China

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China

  • the Central Hospital of Wuhan

    Wuhan, Hubei, China

  • Inner Mongolia Autonomous Region People's Hospital

    Hohhot, Inner Mongolia, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.